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Abstract  
Rationale:  An emerging literature associates increased dopaminergic neurotransmission with altered 
brain response to aversive stimuli in humans. The direction of the effect of dopamine on aversive 
motivation, however, remains unclear, with some studies reporting increased and others decreased 
amygdala activation to aversive stimuli following the administration of dopamine agonists.  Potentiation 
of the startle response by aversive foreground stimuli provides an objective and directional measure of 
emotional reactivity, and is considered useful as an index of the emotional effects of different drugs. 
Objective:  We investigated the effects of two doses of d-amphetamine (5 mg, 10 mg), compared to 
placebo, for the first time to our knowledge, using the affect-startle paradigm.   
Method:   The study employed a between-subjects, double-blind, design, with three conditions: 0 mg 
(placebo), and 5 and 10 mg d-amphetamine (initially n=20/group; final sample: n=18, placebo; n=18, 5 
mg; n=16, 10 mg).  After drug/placebo administration, startle responses (eyeblinks) to intermittent noise 
probes were measured during viewing of pleasant, neutral and unpleasant images.  Participants’ general 
and specific impulsivity and fear-related personality traits were also assessed.  
Results:  The three groups were comparable on personality traits.  Only the placebo group showed 
significant startle potentiation by unpleasant, relative to neutral, images; this effect was absent in both 5-
mg and 10-mg d-amphetamine groups (i.e. the same effect of d-amphetamine observed at different doses 
in different people).   
Conclusions:  Our findings demonstrate a reduced aversive emotional response under d-amphetamine and 
may help to account for the known link between the use of psychostimulant drugs and antisocial 
behaviour.  
 
Key words: d-amphetamine, dopamine, startle potentiation, emotion, affect, antisocial behaviour, 
psychopathic disorder 
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Introduction 
Dopaminergic neurotransmission is widely implicated in appetitive motivation (Berridge and Kringelbach 
2008) and has been associated with tendencies to approach, forage, and explore the environment or to 
experience positive affect states (Gray 1991).  An emerging literature also associates dopamine with 
altered responses to aversive stimuli (Patin and Hurlemann 2011) but the nature of this relationship is 
much less clear.   
 
A number of functional imaging studies have focussed on the effect of dopamine on neural processing of 
aversive stimuli. For example, Delaveau et al. (2007) reported reduced right amygdala activation under the 
dopamine agonist L-DOPA during an emotion (fear and anger) matching task.  Hariri et al. (2002), also 
using an emotion (fear and anger) matching task, found that amphetamine (0.25mg/kg body weight) 
increased right amygdala responses to fear and angry facial expressions.  Furthermore, Takahashi et al. 
(2005) found that a 25-mg single oral dose of sultopridem (a dopamine D2/D3 receptor antagonist) 
reduced activity in the left amygdala when viewing unpleasant images.  Such findings clearly support an 
association between dopamine and processing of aversive stimuli but, being inconsistent in terms of 
enhanced or reduced amygdala activation to unpleasant stimuli, they do not allow a clear picture 
concerning the direction of the effect of dopamine on aversive motivation.   
 
In relation to the influence of dopamine in clinical behaviours, despite the observation that antisocial 
individuals abuse dopamine agonists (e.g., amphetamine and codeine; Fridell et al. 2008) and such long-
term abuse leads to cognitive impairments (review, Ornstein et al. 2000), it is not yet known whether this 
abuse leads to increased appetitive, or decreased aversive, motivation. Nonetheless, the findings 
demonstrating  enhanced learning from reward signals, but also decreased learning from punishment 
signals following dopaminergic therapy in Parkinson’s Disease (Bódi et al. 2009; Cools et al. 2006; Frank 
et al. 2004, 2007; Graef et al. 2010; Kobayakawa et al. 2010), indicate that both appetitive and aversive 
motivational systems are influenced by dopamine.  
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The present study employs, for the first time to our knowledge, the affect-startle paradigm (Vrana et al. 
1988) to understand the effect of dopamine on appetitive and aversive motivation.  Since the introduction 
of this paradigm about 30 years ago, its utility as an objective and reliable tool to assess, and distinguish 
between, the appetitive and aversive motivation systems, in health as well as disease, has been confirmed 
across countries and cultures [for example, in the US (Lang et al. 1990, 2000), UK (Corr et al. 1995; 
Kumari et al. 2001) and Greece (Giakoumaki et al. 2010; Roussos et al. 2009)].  The startle reflex consists 
of a set of involuntary responses to a sudden, strong sensory stimulus (e.g., a loud noise burst) and shows 
reliable modulation by concomitant presentation of affect-toned material: if pleasant, the startle response 
is attenuated; and if unpleasant, it is potentiated (Vrana et al. 1988) - often referred to as ‘pleasure-
attenuated’ and ‘fear-potentiated’ startle, respectively.  Measures of fearfulness and psychopathy show 
positive and negative associations, respectively, with startle potentiation during unpleasant picture 
viewing (e.g. Benning et al. 2005; Herpertz et al. 2001; Vaidyanathan et al. 2011).  Much is known from 
rodent studies about the neural substrates underlying the affect-startle relationship, with critical roles 
played by the amygdala in the potentiation of startle by fear (review, Davis et al. 1993) and the nucleus 
accumbens in the attenuation of startle by pleasure (Koch et al. 1996).   
 
The present study set out to examine the effect of acute administration at two doses of an indirect 
dopamine (D1) agonist, d-amphetamine, on startle modulation by pleasant and unpleasant foreground 
stimuli in healthy volunteers.  On the basis of the literature, we predicted an effect of d-amphetamine on 
indices of both appetitive and aversive motivation. Specifically, given previous suggestions that dopamine 
enhances sensitivity to appetitive stimuli (Fibiger and Phillips 1988) and activates the behavioural 
approach system (BAS; Gray 1991), we predicted that d-amphetamine should enhance pleasure attenuated 
startle.  In addition, given the earlier noted effects of dopaminergic therapy in Parkinson’s Disease and the 
known association between abuse of d-amphetamine and antisocial behaviour where fear-related brakes 
on behaviour seem much weakened, we predicted that it should reduce fear-potentiated startle.  
 5 
 
Method 
Participants and design 
The study involved 60 healthy non-smoking participants (age-range 18-44 years) recruited by local 
advertisements. All potential participants underwent a medical screening for thyroid dysfunction, 
glaucoma, heart disease, hypo- or hypertension, a history of severe mental illness, anorexia, rapid mood 
changes, regular medical prescription, alcohol dependency, lactation or pregnancy, or possibility of 
pregnancy, and excluded if found positive on any of these criteria. Before being accepted, they were 
screened (urine analysis) for drug of abuse (morphine, methadone, cocaine, amphetamines, 
benzodiazepines).  Their blood pressure, heart rate and body weight were also taken, and all selected 
participants were in the normal range.  The study was approved by the Institute of Psychiatry and South 
London and Maudsley NHS Trust research ethics committee. Participants provided written informed 
consent after the study aims and procedures had been explained to them. They were compensated for their 
time and travel.   
 
The study employed a between-subjects design, with three drug conditions: 0 mg (placebo), and 5 and 10 
mg d-amphetamine. Twenty of 60 participants, counterbalanced for sex, were randomly assigned to each 
of the three drug conditions. Of these, two participants of the placebo group, two of the 5 mg drug group, 
and three participants of the 10-mg drug group provided unusable startle data, and the experimental 
session was incomplete for one further participant of the 10-mg drug group.  The final sample thus had 18 
participants in the placebo group, 18 in the 5-mg drug group, and 16 participants in the 10-mg drug. 
Participant characteristics of the final study groups are presented in Table 1. 
 
****Table 1 about here**** 
 
Drug/ Placebo administration 
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The drug was administered orally.  5 mg drug administration consisted of one tablet containing 5 mg 
dexamphetamine (Evans Medical Limited, UK), and 10 mg drug administration consisted of two such 
tablets.  Empty coloured capsules were used as the placebo (0 mg).  Randomisation and drug/placebo 
administration (in a separate room) was carried out by a physician who was not involved in data 
collection.  All participants were given the drug/placebo between 9.30 and 11.00 a.m. to control for the 
possible time of day effects on drug metabolism.  
 
General procedure 
Upon arrival, female participants were given pregnancy tests.  Baseline heart rate and blood pressure were 
then taken from all participants who, then, under double-blind conditions received the drug/placebo.  This 
procedure was followed by a 90-min wait period during which time participants filled out personality 
questionnaires (described further under Personality Measures), and had their heart rate and blood pressure 
monitored every 30 min.  After 90 min following drug/placebo administration, participants performed a 
simple computer learning task (not relevant to this investigation) taking approximately 15 min, and then 
took part in the affect startle experiment.  Heart rate and blood pressure were taken again after the 
experiment.  Participants were requested to have a light breakfast on the day of testing and were served 
only de-caffeinated drinks during the 90-min wait period. They were also requested to abstain from 
alcohol for at least 12 h prior to their appointment.   
 
Affect-startle experiment: paradigm and procedure  
Participants viewed 27 photographic images taken from the International Affective Picture System (IAPS; 
Lang and Bradley 2005). Of these, 9 had positive emotional valence (e.g. pictures of food items, laughing 
babies, happy couple, opposite sex nudes; IAPS nos. 4650, 7200, 7270, 7280, 8120, plus  2030, 4210, 
4180, 4290  used for men, and 2040, 4510, 4520, 4530 used for women), 9 had neutral valence (e.g. 
pictures of household items; IAPS no. 1560, 1640,  2200, 5510, 6610, 7000, 7080, 7100, 7150), and 9 had 
negative emotional valence (e.g. pictures of mutilations, accident victims, snakes, angry faces; IAPS no. 
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1030, 1070, 1110, 3000, 3100, 3140,  6200,  6230, 9050).  The images were arranged in 3 sets of 9 
images, with each set comprising of randomly ordered 3 positive, 3 neutral and 3 negative images.  Each 
image was in view for 6 s, followed by a randomly varying inter-image-interval of 10 to 20 s.  On 6 of 9 
images in each category, an acoustic startle probe, consisting of 50 ms burst of 100 dB white noise with 
almost instantaneous rise time, was delivered at a random point between 2 and 5 s after the image onset.  
In addition to these 18 probes (6 per image category), 6 startle probes were delivered during the inter-
image-intervals to minimise the predictability of probes. At the beginning of the experiment, before the 
images were presented, three startle probes were delivered to reduce habituation during image-presented 
probes.  The sequence of images was same for all participants.   The experimental session started with a 3-
min acclimation period, during which participants were exposed to background (70 dB) white noise only 
(this noise was presented also throughout the entire experimental session). 
 
The equipment and eye-blink recording procedures were identical to those used in our previous studies 
(Kaviani et al. 2004; Kumari et al. 1995, 2001).  A commercially available computerized human startle 
response monitoring system (SR Lab, San Diego, California) delivered the acoustic startle stimuli and 
both recorded and scored electromyographic (EMG) activity for 250 ms, starting from the probe-stimulus 
onset.  Acoustic stimuli were presented binaurally through headphones (Telephonics, TDH 39P).  The 
eyeblink component of the startle response was indexed by recording EMG activity of the orbicularis oculi 
muscle by positioning two miniature silver/silver chloride electrodes filled with Dracard electrolyte paste 
(SLE, Croydon) beneath the left eye. The ground electrode was attached to the mastoid behind the left ear.  
Recorded EMG activity was band-pass filtered, as recommended by the SR-Lab. A 50-hz filter was used 
to eliminate ambient interference.  EMG data were scored off-line by the analytic program of this system 
for response amplitude (in A-D units; the main measure for hypothesis testing) and latency to response 
peak (in ms). Latency to response onset was defined by a shift of 6 digital units from the baseline value 
occurring within 18-100 ms after the stimulus. The latency to response peak was determined as the point 
of maximal amplitude that occurred within 120 ms from the acoustic stimulus.  If the onset and peak 
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latencies differed by more than 95 ms or the baseline values shifted by more than 50 units then the 
responses were rejected (<5% trials).   
 
Prior to the experiment, participants were informed that they were to be shown a series of images of 
varying contents and that they were requested to watch them attentively. Participant was also told that the 
noise (acoustic probes) heard occasionally over the headphones should be ignored.  Testing took place in a 
moderately-lit soundproof laboratory, with the participants sitting comfortably in a large chair.   
 
Personality measures 
Personality was measured by several widely used questionnaires that measure general traits as well as 
specific impulsivity and fear-related ones. General traits of both a positive and negative nature were 
measured by the Tridimensional Personality Questionnaire (TPQ; Cloninger 1988), which yields three 
major scales: Novelty Seeking, Reward Dependence, and Harm Avoidance. Impulsiveness, 
Venturesomeness and Empathy sub-scales of the Impulsiveness-Venturesomeness-Empathy questionnaire 
(IVE-7; Eysenck et al. 1985), which measure positive traits, were also taken. Specific fears were measured 
by the Fear Survey Schedule (Wolpe and Lang 1969). As the drug conditions were between-subjects, 
these measures were taken to ensure that the three drug conditions were comparable in terms of appetitive 
and aversive-related pre-existing individual differences. 
 
Analysis 
The three drug groups were compared on age and personality characteristics using a series of one-way 
analyses of variance (ANOVA).  Data on startle amplitudes during the three image categories were 
subjected to 3 (Drug: 0 mg, 5 mg, 10 mg) x 3 (Valence: positive, neutral, negative) ANOVA with Drug 
and Sex as between-subjects factors and Valence as a within-subjects factor, followed by lower-order 
ANOVAs and post-hoc t-tests to examine the Drug x Valence interaction.  Prior to running these analyses 
the data were examined for their distribution properties and found to be near-normal (slightly 
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positively skewed) with equal error variance in each category across the study groups. All analyses 
were carried out using Statistical Package for the Social Sciences (SPSS, version 18) with alpha level for 
significance testing maintained at p ≤0.05.    
 
Results 
Participant characteristics  
The three drug groups were comparable on age and personality dimensions (Table 1).  
 
Startle modulation 
Amplitude served as the main dependent measure of startle reactivity.1  As expected, there was a 
significant main effect of Valence [F (2,92)=3.50, p=0.03; Huynh-Feldt corrected p=0.04] and a 
significant Drug x Valence interaction [F (4,92)=2.54, p=0.04; Huynh-Feldt corrected p=0.057]. This 
interaction obscured the main effect of Drug which was not significant [F (2,46)=0.08, p=0.92].  Sex [F 
(1, 46)=0.064, p=0.80] was non-significant, and there were no significant interactions involving this factor 
(p values > 0.20 for Sex x Drug, Sex x Valence, and Sex x Drug x Valence].    
 
Examination of Valence effect (categories ordered as positive, neutral, negative) separately in the three 
drug groups revealed a significant main effect of Valence [F (2,34)=4.71, p=0.016; Huynh-Feldt corrected 
p=0.021] with a linear trend [Lin F (1,17)=8.50, p=0.01] in the placebo group, but not in the 5 mg [F 
(2,34)=2.48, p=0.10] or 10 mg [F (2,30)=1.81, p=0.18] drug groups.    
 
Probing the Drug x Valence interaction further using 3 (Drug) x 2 (Valence: Positive and Neutral; or 
Negative and Neutral) ANOVAs did not show a significant effect of Drug on startle attenuation by 
                                                 
1
 We conducted comparable analyses for latency of response but no effects were found. 
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positive images [F (2, 49)=1.72, p=0.19]. There was, however, an effect of drug on startle potentiation by 
negative, relative to neutral, images [F (2, 49)=3.76, p=0.03; Huynh-Feldt corrected p=0.03]: significant 
startle potentiation by negative, relative to neutral, images was present in the placebo group [F 
(1,17)=5.35, p=0.03; Huynh-Feldt corrected p=0.03] but was absent in both drug groups [5 mg: F (1, 
17)=0.99, p=0.33; 10 mg: F (1, 15)=1.13, p=0.30]. Importantly, the three groups did not differ in startle 
amplitude during the viewing of neutral images itself [F (2, 49)=0.41, p=0.67].  
 
***Figure 1 about here**** 
 
Discussion 
The human startle reflex is potentiated by aversive foreground stimuli and attenuated by pleasant 
foreground stimuli; these are often referred to as ‘fear-potentiated’ and ‘pleasure-attenuated’ startle, 
respectively. The startle reflex provides a convenient and sensitive measure of emotional reactivity and is 
especially useful for examining drug effects on emotion. Our study is the first to show that a potent 
dopamine (D1) agonist, d-amphetamine, significantly reduces fear-potentiated startle, abolishing this 
effect seen in placebo.  This effect of d-amphetamine was observed at two doses (5 and 10-mg) and the 
pattern of effects observed in both drug groups was virtually identical, suggesting the absence of a dose-
related effect – the identical pattern of these effects also provides evidence that the observed drug effect 
was not a Type I error.  It thus appears that d-amphetamine blunts the induction of negative emotional 
experience, at least as measured by the affect-startle paradigm. There were no effects of sex on this effect; 
and the differential pattern of findings observed between the drug and placebo conditions could not be 
attributed to pre-existing personality differences, assessed by broad dimensions of personality or specific 
appetitive and aversive-related traits. 
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Results may be interpreted as showing that dopamine (D1) agonism reduces fear-related emotional 
processes, which may account for the known link between the use of this psychostimulant drug and 
antisocial behaviour, noted in the Introduction. Specifically, these data are consistent with the observation 
that, even with acute administration of d-amphetamine, a less fearful emotional response can be observed 
in healthy people of both sexes. Certainly, these findings are consistent with other research which shows 
that psychopathic-related disposition in young (non-clinical) individuals are related to a hyperactive 
behaviour approach system and a appetitive motivation in general as well as to reduced fear (and anxiety) 
(Corr 2010).  There is robust evidence for impaired startle potentiation to aversive stimuli (e.g. Benning et 
al. 2005; Herpertz et al. 2001; Patrick et al. 1993; Vaidyanathan et al. 2011) as well as amygdala 
dysfunction (reviews, Blair 2010; Gao et al. 2009) in psychopathic individuals. Given consistent evidence 
from both animal (review, Davis et al. 1993) and human studies (e.g. Aldhafeeri et al. 2012; Buchanan et 
al. 2004; Funayama et al., 2001) that startle potentiation by aversive stimuli is mediated by the amygdala, 
which has a high density of dopamine receptors (Missale et al. 1998), and is influenced by dopamine 
transmission (Kroner et al. 2005),  our findings point to two possible explanations: (a) that d-amphetamine 
directly antagonises fear-related processes; or  (b) this effect is secondary to a primary effect on pleasure-
related processes (there is a long and well-established literature showing mutually reciprocal inhibition of 
appetitive and aversive systems; Gray 1987). In support of the latter possibility, there is evidence of 
neurochemical and neurophysiological hyperactivity in the mesolimbic dopamine reward system in 
psychopathic individuals (Buckholtz et al. 2010).  However, the effect of d-amphetamine observed in this 
study may not be exclusively dopaminergic since d-amphetamine not only releases dopamine, but also 
serotonin and noradrenaline (West et al. 1995), and  both the serotonergic and noradrenergic systems are 
also implicated in emotion processing (Bijlsma et al. 2010; Hung et al. 2011) as well as startle reactivity 
(Koch et al. 1999).   
 
Relating these findings to non-clinical and clinical groups of antisocial and psychopathic individuals 
should yield valuable data, especially concerning their relative reactions to appetitive and aversive stimuli, 
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and how different classes of drugs affect their responses. As noted by Fridell et al. (2008, p. 799), crime 
and drug abuse go together and amphetamine, in particular, is associated with crime in general, as well as 
with all subtypes of crime. Miller et al. (2006) provides estimates of the many millions of crime 
committed in the USA by individual using drugs of abuse.  It might be the case that certain individuals 
have a vulnerability to reduced aversive motivation in the context of hyperdopamingeric activity; and it 
might be these people that are prone to develop antisocial and psychopathic personalities. This hypothesis 
could be tested by behavioural and MRI reactions to drug challenge. It might also be important to test this 
hypothesis in younger children in order to throw light on the developmental trajectory of such vulnerable 
individuals.  
 
Limitations of this research include the use of a between-subjects design; however, for a first study 
examining d-amphetamine and affect-modulated startle reactivity, this could be seen as a strength 
especially as the groups are well matched on personality dimensions relevant to affective startle 
modulation (e.g., Harm Avoidance; Corr et al. 1995, 1997).  Perhaps more relevant is the acute vs. chronic 
dimension of d-amphetamine on emotional experience and reactivity, which was not assessed in this 
study. It would be important to determine in future work whether chronic administration of amphetamine 
results in a chronic reduction in aversive motivation.    
 
In conclusion, two doses of d-amphetamine (5 and 10-mg) were found to abolish the fear-potentiated 
startle seen in the placebo group, which indicates that, for the first time, acute administration of this 
dopamine agonist is related to reduced aversive motivation and reactivity to unpleasant stimuli. These 
results point to new a hypothesis concerning the psychopharmacological basis of antisocial and, perhaps 
even, psychopathic behaviour, and helps to explain previously observed associations between 
hyperdopamingeric activity and appetitive motivation, on the one hand, and antisocial behaviour, on the 
other hand.  
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Table 1: Participant characteristics.  
 
 Placebo Group 
10 Men, 8 Women 
5 mg Drug Group 
8 Men, 10 Women 
10 mg Drug Group 
9 Men, 7 Women 
ANOVA 
(df=2,49)  
 Mean (SD) Mean (SD) Mean (SD)  
Age (yrs) 27.90 (4.80) 29.94 (6.93) 27.69 (5.31) F=0.82, p=0.45 
TPQ     
Novelty Seeking 18.28 (4.97) 18.67 (5.65) 18.25 (3.66) F=0.04, p=0.96 
Reward Dependence 18.61 (4.73) 17.17 (4.19) 16.69 (6.46) F=0.65, p=0.52 
Harm Avoidance 13.11 (5.77) 12.17 (5.89) 12.88 (6.08) F=0.20, p=0.82 
IVE-7     
Impulsiveness 7.89 (5.20) 9.17 (3.45) 8.06 (3.99) F=0.47, p=0.63 
Venturesomeness  10.00 (3.79)                10.94 (3.89) 9.19 (3.49) F=0.94, p=0.40 
Empathy 12.83 (3.68) 12.06 (2.53) 13.12 (2.75) F=0.58, p=0.57 
Fear Survey Schedule 
Score 
116.56 (27.07) 117.39 (26.23) 120.81 (26.10) F=0.12, p=0.89 
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Figure Caption 
Figure 1:  Affective startle modulation in the placebo and drug groups. Error bars display +1SEM.  
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